Myc proteins in brain tumor development and maintenance.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed, 38 citations in OpenAlex.

1. Metformin and glioma: Targeting metabolic dysregulation for enhanced therapeutic outcomes.Translational oncology · 2025
   Review
2. SIRT5 promote malignant advancement of chordoma by regulating the desuccinylation of c-myc.BMC cancer · 2024
   Article
3. Epigenetic-Based Therapy-A Prospective Chance for Medulloblastoma Patients' Recovery.International journal of molecular sciences · 2021
   Review
4. MicroRNA-196a promotes renal cancer cell migration and invasion by targeting BRAM1 to regulate SMAD and MAPK signaling pathways.International journal of biological sciences · 2021
   Article
5. MYC in Brain Development and Cancer.International journal of molecular sciences · 2020
   Review
6. Nuclear Receptor Binding Protein 2 Is Downregulated in Medulloblastoma, and Reduces Tumor Cell Survival upon Overexpression.Cancers · 2020
   Article
7. Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics.Cells · 2019
   Review
8. MiR-27a: A Novel Biomarker and Potential Therapeutic Target in Tumors.Journal of Cancer · 2019
   Review
9. Exploration of Involved Key Genes and Signaling Diversity in Brain Tumors.Cellular and molecular neurobiology · 2018
   Review
10. Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas.PloS one · 2018
    Article
11. Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond.Molecular carcinogenesis · 2017
    Review
12. Molecular Testing of Brain Tumor.Journal of pathology and translational medicine · 2017
    Review
13. Deregulated proliferation and differentiation in brain tumors.Cell and tissue research · 2015
    Review
14. MicroRNA-27a distinguishes glioblastoma multiforme from diffuse and anaplastic astrocytomas and has prognostic value.American journal of cancer research · 2015
    Article
15. Signals that regulate the oncogenic fate of neural stem cells and progenitors.Experimental neurology · 2014
    Review
16. Oncoprotein stabilization in brain tumors.Oncogene · 2014
    Review
17. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.Oncotarget · 2014
    Article
18. Pou5f1/Oct4 promotes cell survival via direct activation of mych expression during zebrafish gastrulation.PloS one · 2014
    Article
19. NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200.Neuro-oncology · 2013
    Article
20. Retroviral oncogenes: a historical primer.Nature reviews. Cancer · 2012
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as